Astral
Payments companies reported to CMS as associated with Astral. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Astral, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Astral
These are the largest totals companies reported as associated with Astral. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Krishnan Rajagopal | Rochester, IN | Pulmonary Disease | $23.39 |
| Marc Diamond | Philadelphia, PA | Pulmonary Disease | $20.79 |
| Anuj Shukla | Danville, IN | Pulmonary Disease | $17.81 |
| Sumit Chawla | Danville, IN | Pulmonary Disease | $17.81 |
| Lirim Krveshi | Danville, IN | Pulmonary Disease | $17.81 |
| Sami Abuqayyas | Danville, IN | Pulmonary Disease | $17.80 |
Prescribed Astral?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.